[A case of distal cholangiocarcinoma with high sensitivity to neoadjuvant chemoradiation therapy].
We hypothesized that neoadjuvant chemoradiation therapy for cholangiocarcinoma (NACRAC) using gemcitabine would improve the prognosis of resected cases. Phase II trial of NACRAC is ongoing. We report a very effective case to NACRAC for distal cholangiocarcinoma, which markedly reduced the size and levels of the tumor markers. The patient was a 50- year-old man who presented jaundice. Serum tumor markers were clearly elevated, and abdominal CT scan revealed an enhanced mass in the lower bile duct, a dilatation of the intrahepatic to the middle bile duct and a swollen regional lymph node. After NACRAC, the tumor markers were decreased within a normal range. Also on CT scan, the main tumor was slightly detectable and the swollen node was reduced more than 30% in short diameter. Therefore, the effect of NACRAC was considered PR in RECIST guidelines (ver.1 .1). Pancreaticoduodenectomy was performed 2 weeks after NACRAC. No perioperative complications occurred. Pathological examination showed a good response, Grade 2b on Oboshi-Shimosato's classification. In this case, NACRAC had a good effect in imaging and pathological findings as well as in the tumor markers. Therefore, the neoadjuvant chemoradiation therapy has a potential to improve the prognosis for cholangiocarcinoma.
Dept. of Surgery, Division of Digestive Surgery, Tohoku University Graduate School of Medicine.
Yoichi
Y
Haji
Masamichi
M
Mizuma
Hiroki
H
Hayashi
Kei
K
Nakagawa
Takaho
T
Okada
Hideo
H
Otsuka
Shigeru
S
Ottomo
Naoaki
N
Sakata
Koji
K
Fukase
Hiroshi
H
Yoshida
Tohru
T
Onogawa
Fuyuhiko
F
Motoi
Takeshi
T
Naito
Toshiki
T
Rikiyama
Yu
Y
Katayose
Shinichi
S
Egawa
Michiaki
M
Unno
D001650:Bile Duct Neoplasms / Q000473:pathology / Q000628:therapy*; D001653:Bile Ducts, Intrahepatic / Q000473:pathology*; D059248:Chemoradiotherapy; D018281:Cholangiocarcinoma / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009361:Neoplasm Invasiveness; D014057:Tomography, X-Ray Computed